DIAGNOS Seeks FDA Classification for AI-Powered Retinal Analysis System
Event summary
- DIAGNOS submitted a Section 513(g) Request for Information to the FDA regarding its CARA System on September 28, 2026.
- The submission follows a previous FDA Pre-Submission filing and addresses specific regulatory recommendations.
- CARA System combines AI-powered analytics with clinician annotations for retinal disease detection.
- DIAGNOS targets the U.S. optometry market of approximately 49,500 practitioners with this regulatory step.
The big picture
DIAGNOS' FDA submission represents a critical step in its strategy to expand its AI-powered retinal analysis system into the U.S. market. The company is pursuing a separate regulatory pathway while maintaining its existing Canadian license, targeting a significant opportunity in optometric practice. This move comes as AI-assisted diagnostic tools gain traction in healthcare, promising to streamline workflows and improve early detection of retinal diseases.
What we're watching
- Regulatory Timing
- How quickly the FDA will respond to DIAGNOS' Section 513(g) request and whether it will require additional data.
- Market Expansion
- Whether DIAGNOS can successfully navigate separate regulatory pathways in the U.S. and Canada.
- Competitive Positioning
- The pace at which DIAGNOS can establish market share against existing retinal imaging solutions.